Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China flag China · Delayed Price · Currency is CNY
15.24
-0.44 (-2.81%)
At close: Nov 13, 2026

SHE:301246 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,5271,9031,7422,0262,0461,568
Other Revenue
36.7836.7828.6928.8717.739.44
2,5641,9391,7712,0552,0641,578
Revenue Growth
45.20%9.53%-13.83%-0.43%30.79%21.10%
Cost of Revenue
2,0241,6151,5901,8141,6221,051
Gross Profit
539.1324.06180.95240.49442.18526.52
Selling, General & Admin
119.12110.2391.3898.5102.96108.41
Research & Development
101.7983.959.1868.8264.0148.71
Other Operating Expenses
7.966.46-5.411.799.4612.27
Operating Expenses
233.41207.41145.67176.55180.73170.42
Operating Income
305.69116.6635.2863.94261.45356.11
Interest Expense
-15.28-13.79-12-13.4-3.41-2.38
Interest & Investment Income
88.7937.6214.1236.47172.05192.11
Currency Exchange Gain (Loss)
-1.38-1.385.631.1113.64-2.62
Other Non Operating Income (Expenses)
-18.142.21-1.73-8.43-3.09-1.02
EBT Excluding Unusual Items
359.68141.3141.3179.69440.65542.21
Impairment of Goodwill
------6.5
Gain (Loss) on Sale of Investments
-0.211.853.822.86--
Gain (Loss) on Sale of Assets
-4.680.770.530.5714.44-0.62
Asset Writedown
7.58-10.81-0.27--1.97-0.76
Other Unusual Items
12.5912.5914.315.4424.8510.72
Pretax Income
374.96145.7259.6998.56477.98545.04
Income Tax Expense
72.2428.098.2311.3943.1851.19
Earnings From Continuing Operations
302.72117.6351.4687.17434.8493.85
Minority Interest in Earnings
1.671.420---
Net Income
304.39119.0551.4787.17434.8493.85
Net Income to Common
304.39119.0551.4787.17434.8493.85
Net Income Growth
2040.18%131.33%-40.96%-79.95%-11.96%92.02%
Shares Outstanding (Basic)
400397399388353353
Shares Outstanding (Diluted)
400397399388353353
Shares Change
1.46%-0.42%2.71%10.02%-0.00%0.13%
EPS (Basic)
0.760.300.130.221.231.40
EPS (Diluted)
0.760.300.130.221.231.40
EPS Growth
2009.39%132.30%-42.52%-81.78%-11.96%91.78%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-147.06-341.06-176.01-439.39-292.1-62.92
Free Cash Flow Per Share
-0.37-0.86-0.44-1.13-0.83-0.18
Dividend Per Share
0.0500.0500.0300.0500.100-
Dividend Growth
66.67%66.67%-40.00%-50.00%--
Gross Margin
21.03%16.71%10.22%11.70%21.43%33.37%
Operating Margin
11.92%6.02%1.99%3.11%12.67%22.57%
Profit Margin
11.87%6.14%2.91%4.24%21.07%31.30%
Free Cash Flow Margin
-5.74%-17.59%-9.94%-21.38%-14.15%-3.99%
EBITDA
524.98318.14213.02220.09350.53435.77
EBITDA Margin
20.48%16.40%12.03%10.71%16.98%27.62%
D&A For EBITDA
219.29201.48177.74156.1689.0879.66
EBIT
305.69116.6635.2863.94261.45356.11
EBIT Margin
11.92%6.02%1.99%3.11%12.67%22.57%
Effective Tax Rate
19.27%19.27%13.79%11.56%9.03%9.39%
Revenue as Reported
2,5641,9391,7712,0552,0641,578
Advertising Expenses
-1.291.030.80.020.69